Faraday Monthly Sales Report -- March 2008
HSINCHU, TAIWAN -- April 7, 2008 -- Faraday Technology Corporation (TAIEX: 3035) (“Faraday”) today announced that revenues for March 2008 totaled NT$388,652 thousands, 3.9% up from the same period last year.
Table 1: Faraday March Sales Report (Unit: NT$ thousand)
Revenues | 2008 | 2007 | YoY Change |
March | 388,652 | 374,015 | 3.9% |
Table 2: March Sales Breakdown (Unit: NT$ thousand)
Product Items | Revenue |
ASIC Mass Production | 298,907 |
ASIC Design Service | 18,532 |
IP | 71,213 |
Total | 388,652 |
Note: Year 2008 revenue figures have not been audited.
About Faraday Technology Corporation
Faraday Technology Corporation is a leading silicon IP and fabless ASIC vendor. The company's broad silicon IP portfolio includes Cell Library ,Memory Compiler,ARM-compliant CPUs, DDRII, MPEG4, H.264, USB 2.0, 10/100 Ethernet, Serial ATA, PCI Express, and UWB . With 2007 revenue of US$ 156 million, Faraday is one of the largest fabless ASIC companies in the Asia-Pacific region, and it also has a significant presence in other world-wide markets. Headquartered in Taiwan , Faraday has service and support offices around the world, including the U.S. , Japan , Europe, and China . For more information, please visit : www.faraday-tech.com
|
Faraday Technology Corp. Hot IP
Related News
Breaking News
- RISC-V International Promotes Andrea Gallo to CEO
- See the 2025 Best Edge AI Processor IP at the Embedded Vision Summit
- Andes Technology Showcases RISC-V AI Leadership at RISC-V Summit Europe 2025
- RISC-V Royalty-Driven Revenue to Exceed License Revenue by 2027
- Keysom Unveils Keysom Core Explorer V1.0
Most Popular
- RISC-V International Promotes Andrea Gallo to CEO
- See the 2025 Best Edge AI Processor IP at the Embedded Vision Summit
- Andes Technology Showcases RISC-V AI Leadership at RISC-V Summit Europe 2025
- Ceva, Inc. Announces First Quarter 2025 Financial Results
- Cadence Unveils Millennium M2000 Supercomputer with NVIDIA Blackwell Systems to Transform AI-Driven Silicon, Systems and Drug Design
![]() |
E-mail This Article | ![]() |
![]() |
Printer-Friendly Page |